A critical update on the immunopathogenesis of Stiff Person Syndrome

European Journal of Clinical Investigation

Volumn 40, Issue 11, 2010, Pages 1018-1025

  Alexopoulos, Harry ^a   Dalakas, Marinos C ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmunity; GABAergic synapse; GABARAP; Glutamic acid decarboxylase; Nervous system

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY;

AUTOIMMUNITY; CEREBROSPINAL FLUID; GABAERGIC SYSTEM; HUMAN; IMMUNOPATHOGENESIS; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; STIFF MAN SYNDROME; SYNAPSE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; STIFF-PERSON SYNDROME;

EID: 78649490609     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02340.x     Document Type: Review

References (70)

1. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000;55:1531-5.
2. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-6.
3. Dalakas MC. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. J Neurol 2006;253(Suppl 5):V25-32.
4. Murinson BB. Stiff-person syndrome. Neurologist 2004;10:131-7.
5. Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 2004;61:902-4.
6. Ameli R, Snow J, Rakocevic G, Dalakas MC. A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology 2005;64:1961-3.
7. Meinck HM, Ricker K, Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry 1984;47:280-7.
8. Solimena M, Butler MH, De Camilli P. GAD, diabetes, and Stiff-Man syndrome: some progress and more questions. J Endocrinol Invest 1994;17:509-20.
9. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553-63.
10. Burns TM. A step forward for stiff-person syndrome. Lancet 2005;365:1365-7.
11. Meinck HM. Stiff man syndrome. CNS Drugs 2001;15:515-26.
12. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993;178:2097-106.
13. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 1991;10:1275-84.
14. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988;318:1012-20.
15. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998;44:194-201.
16. Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 1991;14:452-7.
17. Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001;57:780-4.
18. Skorstad G, Hestvik AL, Torjesen P, Alvik K, Vartdal F, Vandvik B et al. GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. Eur J Neurol 2008;15:973-80.
19. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 2005;175:7755-62.
20. Baekkeskov S, Kanaani J, Jaume JC, Kash S. Does GAD have a unique role in triggering IDDM? J Autoimmun 2000;15:279-86.
21. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007;61:544-51.
22. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994;180:595-606.
23. Al-Bukhari TA, Radford PM, Bouras G, Davenport C, Trigwell SM, Bottazzo GF et al. Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis. Clin Exp Immunol 2002;130:131-9.
24. Burbelo PD, Groot S, Dalakas MC, Iadarola MJ. High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun 2008;366:1-7.
25. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-7.
26. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo MJ et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001;107:555-64.
27. Hassin-Baer S, Kirson ED, Shulman L, Buchman AS, Bin H, Hindiyeh M et al. Stiff-person syndrome following West Nile fever. Arch Neurol 2004;61:938-41.
28. Koerner C, Wieland B, Richter W, Meinck HM. Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology 2004;62:1357-62.
29. Sandbrink F, Syed NA, Fujii MD, Dalakas MC, Floeter MK. Motor cortex excitability in stiff-person syndrome. Brain 2000;123 (Pt 11):2231-9.
30. Rossi S, Ulivelli M, Malentacchi M, Greco G, Bartalini S, Borgogni P et al. Effects of immunotherapy on motor cortex excitability in Stiff Person Syndrome. J Neurol 2010;257:281-5.
31. Floeter MK, Valls-Sole J, Toro C, Jacobowitz D, Hallett M. Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology 1998;51:85-93.
32. Gilbert SL, Zhang L, Forster ML, Anderson JR, Iwase T, Soliven B et al. Trak1 mutation disrupts GABA(A) receptor homeostasis in hypertonic mice. Nat Genet 2006;38:245-50.
33. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 2005;62:970-4.
34. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord 2002;17:853-66.
35. Nemni R, Caniatti LM, Gironi M, Bazzigaluppi E, De Grandis D. Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology 2004;62:2101-2.
36. Burns TM, Jones HR, Phillips LH II, Bugawan TL, Erlich HA, Lennon VA. Clinically disparate stiff-person syndrome with GAD65 autoantibody in a father and daughter. Neurology 2003;61:1291-3.
37. Chang T, Pettingill P, Alexopoulos H, Jacobson LW, Brown P, Vincent A. Autoantibodies to GAD and cell surface determinants in stiff person syndrome. Neurology 2009;72:A472.
38. Elliott JF, Qin HY, Bhatti S, Smith DK, Singh RK, Dillon T et al. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes 1994;43:1494-9.
39. Han G, Li Y, Wang J, Wang R, Chen G, Song L et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol 2005;174:4516-24.
40. Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P, Solimena M. Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 2004;63:2146-8.
41. Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic? Brain 2008;131:2536-7.
42. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, De Andres C et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001;58:225-30.
43. Giometto B, Miotto D, Faresin F, Argentiero V, Scaravilli T, Tavolato B. Anti-gabaergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia. J Neurol Sci 1996;143:57-9.
44. Kim JY, Chung EJ, Kim JH, Jung KY, Lee WY. Response to steroid treatment in anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia, stiff person syndrome and polyendocrinopathy. Mov Disord 2006;21:2263-4.
45. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 2006;67:1068-70.
46. Ishida K, Mitoma H, Song SY, Uchihara T, Inaba A, Eguchi S et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999;46:263-7.
47. Mitoma H, Song SY, Ishida K, Yamakuni T, Kobayashi T, Mizusawa H. Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. J Neurol Sci 2000;175:40-4.
48. Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K, Palmio J et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000;55:46-50.
49. Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, Mucignat C. Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab). Exp Neurol 2006;202:514-8.
50. Vianello M, Bisson G, Dal Maschio M, Vassanelli S, Girardi S, Mucignat C et al. Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. Autoimmunity 2008;41:66-73.
51. Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000;26:307-12.
52. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993;328:546-51.
53. De CamilliP, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993;178:2219-23.
54. Takei K, Slepnev VI, Haucke V, De Camilli P. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1999;1:33-9.
55. Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005;365:1406-11.
56. Geis C, Beck M, Jablonka S, Weishaupt A, Toyka KV, Sendtner M et al. Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca(2+)]i rise in embryonic motoneurons. Neurobiol Dis 2009;36:191-9.
57. Chen L, Wang H, Vicini S, Olsen RW. The gamma-aminobutyric acid type A (GABAA) receptor-associated protein (GABARAP) promotes GABAA receptor clustering and modulates the channel kinetics. Proc Natl Acad Sci U S A 2000;97:11557-62.
58. Raju R, Rakocevic G, Chen Z, Hoehn G, Semino-Mora C, Shi W et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006;129:3270-6.
59. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519-25.
60. Lohmann T, Hawa M, Leslie RD, Lane R, Picard J, Londei M. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. Lancet 2000;356:31-5.
61. Costa M, Saiz A, Casamitjana R, Castaner MF, Sanmarti A, Graus F et al. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clin Exp Immunol 2002;129:471-8.
62. Skorstad G, Hestvik AL, Vartdal F, Holmoy T. Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome. J Autoimmun 2009;32:24-32.
63. Zekzer D, Wong FS, Ayalon O, Millet I, Altieri M, Shintani S et al. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 1998;101:68-73.
64. Burton AR, Baquet Z, Eisenbarth GS, Tisch R, Smeyne R, Workman CJ et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4(+) T cells. J Immunol 2010;184:4863-70.
65. Raju R, Hampe CS. Immunobiology of stiff-person syndrome. Int Rev Immunol 2008;27:79-92.
66. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009;11:102-10.
67. Knopf PM, Harling-Berg CJ, Cserr HF, Basu D, Sirulnick EJ, Nolan SC et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol 1998;161:692-701.
68. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010;257:509-17.
69. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999;131:522-30.
70. Hutchinson M, Waters P, McHugh J, Gorman G, O'Riordan S, Connolly S et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008;71:1291-2.